Patient Characteristics
| Characteristic . | No. (%) . |
|---|---|
| Patients | 245 |
| Patients with siblings | 199 (81) |
| HLA-typed patients | 162 (81) |
| Patients with/without donors | 80 (49)/82 (51) |
| Male | 140 (57) |
| Mean age, y (range) | 55 (30-65) |
| Durie & Salmon stage I-II | 73 (30) |
| Durie & Salmon stage III | 172 (70) |
| Ig-G myeloma | 133 (54) |
| Ig-A myeloma | 50 (20) |
| Ig-M myeloma | 1 (< 1%) |
| Bence Jones myeloma | 49 (20) |
| Non-secretory myeloma | 12 (5) |
| β-2-microglobulin ≥ 3.5 mg/dL | 76/220 (35) |
| Albumin < 3.5 g/dL | 42/204 (21) |
| Creatinine ≥ 2 mg/dL | 30 (12) |
| LDH above normal level | 38/210 (18) |
| Presence of Ch 13 deletion | 31/85 (36) |
| Characteristic . | No. (%) . |
|---|---|
| Patients | 245 |
| Patients with siblings | 199 (81) |
| HLA-typed patients | 162 (81) |
| Patients with/without donors | 80 (49)/82 (51) |
| Male | 140 (57) |
| Mean age, y (range) | 55 (30-65) |
| Durie & Salmon stage I-II | 73 (30) |
| Durie & Salmon stage III | 172 (70) |
| Ig-G myeloma | 133 (54) |
| Ig-A myeloma | 50 (20) |
| Ig-M myeloma | 1 (< 1%) |
| Bence Jones myeloma | 49 (20) |
| Non-secretory myeloma | 12 (5) |
| β-2-microglobulin ≥ 3.5 mg/dL | 76/220 (35) |
| Albumin < 3.5 g/dL | 42/204 (21) |
| Creatinine ≥ 2 mg/dL | 30 (12) |
| LDH above normal level | 38/210 (18) |
| Presence of Ch 13 deletion | 31/85 (36) |